GlassScriptPhysician profile
Richard Mascolo
NPI 1225079965
$2,387.20
in general payments reported to CMS, 2019-2025
20 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $156 · 2021: $183 · 2022: $416 · 2023: $605 · 2024: $452 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $419.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $242.93 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $223.43 | 2019-2023 | Xarelto |
| Pfizer INC. | $207.20 | 2019-2025 | |
| Amgen INC. | $195.74 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $186.32 | 2019-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.83 | 2022-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $115.17 | 2024 | Arcalyst |
| Medtronic, INC. | $114.79 | 2023 | Corevalve Evolut R |
| Sanofi-Aventis U.S. LLC | $103.49 | 2019-2023 | |
| Amarin Pharma, INC. | $102.62 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $56.56 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $49.34 | 2023-2024 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $48.95 | 2025 | Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $45.18 | 2024-2025 | Nexletol |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $41.58 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $37.25 | 2023 | |
| Boston Scientific Corporation | $28.44 | 2023 | Watchman Access System |
| Inspire Medical Systems, INC. | $23.66 | 2025 | Inspire |
| Scpharmaceuticals INC. | $16.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mascolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.